AIG
XLO icon

American International Group’s Xilio Therapeutics XLO Stock Holding History

American International Group’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-271
Closed -$27K – 3284
2022
Q1 		$27K Sell
271
-11
-4% -$1.74K ﹤0.01% 2994
2021
Q4 		$63K Buy
+282
New +$67.2K ﹤0.01% 2888

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

American International Group's XLO Position: Q2 2022 in Review

American International Group sold out of Xilio Therapeutics (XLO) in Q2 2022, closing a stake of 271 shares — an estimated $27K sold.

American International Group first reported a position in XLO in Q4 2021 and held it in 2 quarters. The position peaked at $63K in Q4 2021. 32 funds tracked by Wall St. Rank hold XLO as of Q2 2022.

  • American International Group reported no remaining Xilio Therapeutics position as of Q2 2022 after selling out during the quarter.
  • American International Group sold 271 Xilio Therapeutics shares in Q2 2022, an estimated $27K.
  • American International Group first reported a position in Xilio Therapeutics in Q4 2021 and held it in 2 quarters.
  • American International Group's Xilio Therapeutics position peaked at $63K in Q4 2021.
  • 32 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2022.

Based on American International Group's 13F filing for Q2 2022, filed 12 Aug 2022.